<br />
GASTROENTEROLOGY<br />
ECCO supplement • emjreviews.com<br />
INSIDE<br />
In It for the Long Haul: Managing<br />
the Complexity of Crohn’s Disease<br />
Management of Ulcerative Colitis:<br />
Putting Patients at the Centre<br />
IN IT FOR THE LONG HAUL: MANAGING THE<br />
COMPLEXITY OF CROHN’S DISEASE<br />
Summary of presentations from the Takeda-Sponsored<br />
Symposium held on at the 11th Congress of the European Crohn’s<br />
and Colitis Organisation (ECCO) in Amsterdam, Netherlands,<br />
on 18th March 2016<br />
Chairperson<br />
Michael A. Kamm1<br />
Speakers<br />
Michael A. Kamm,1 Remo Panaccione,2 Stefan Schreiber3<br />
1. St Vincent’s Hospital, Melbourne, Australia<br />
2. Inflammatory Bowel Disease Group, University of Calgary, Calgary, Canada<br />
3. Department of General Internal Medicine, Christian-Albrechts-Universität zu Kiel,<br <a title="EMJ Gastroenterol. 2016 Suppl 6 page 1" href="http://viewer.zmags.com/publication/d138ddab?page=1"> GASTROENTEROLOGY ECCO supplement • emjreviews.com</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 2" href="http://viewer.zmags.com/publication/d138ddab?page=2"> IN IT FOR THE LONG HAUL: MANAGING THE COM</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 3" href="http://viewer.zmags.com/publication/d138ddab?page=3"> showed it to be effective versus placebo, in term</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 4" href="http://viewer.zmags.com/publication/d138ddab?page=4"> of a patient-tailored assessment. Furthermore</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 5" href="http://viewer.zmags.com/publication/d138ddab?page=5"> GEMINI 2 </a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 6" href="http://viewer.zmags.com/publication/d138ddab?page=6"> Week 30 was 21% (23/110) in those who received re</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 7" href="http://viewer.zmags.com/publication/d138ddab?page=7"> performed throughout the study and after a </a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 8" href="http://viewer.zmags.com/publication/d138ddab?page=8"> Table 1: Summary of the data for vedolizumab in r</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 9" href="http://viewer.zmags.com/publication/d138ddab?page=9"> The primary endpoint was steroid-free remission a</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 10" href="http://viewer.zmags.com/publication/d138ddab?page=10"> REFERENCES 1. Sartor RB. Mechanisms of dise</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 11" href="http://viewer.zmags.com/publication/d138ddab?page=11"> Consortium. Abstract 1904. Annual Scientific</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 12" href="http://viewer.zmags.com/publication/d138ddab?page=12"> MANAGEMENT OF ULCERATIVE COLITIS: PUTTING PAT</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 13" href="http://viewer.zmags.com/publication/d138ddab?page=13"> Introduction Doctor Iris Dotan Management of UC</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 14" href="http://viewer.zmags.com/publication/d138ddab?page=14"> TNF antagonists have also been shown to double th</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 15" href="http://viewer.zmags.com/publication/d138ddab?page=15"> sedimentation rate >30 mm/hour, heart rate ></a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 16" href="http://viewer.zmags.com/publication/d138ddab?page=16"> PBO (n=149) 100 VDZ (n=225) 80 60 Patients,</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 17" href="http://viewer.zmags.com/publication/d138ddab?page=17"> Table 1: Post-approval experience with vedolizuma</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 18" href="http://viewer.zmags.com/publication/d138ddab?page=18"> Conclusion Employing a patient-centric chro</a>
<a title="EMJ Gastroenterol. 2016 Suppl 6 page 19" href="http://viewer.zmags.com/publication/d138ddab?page=19"> as Induction Therapy in Refractory IBD Patients: </a>